All News

An expert discusses the recent approval for Retevmo for RET-positive pediatric thyroid cancer and ongoing research for this patient population.

My oncologist said that having a supportive community during cancer is just as important as treatment and I could not agree more — it makes me thankful.

Dato-DXd did not improve survival in the overall population with non-small cell lung cancer but did boost outcomes in patients with non-squamous disease.

For patients with kidney cancer undergoing postsurgical treatments, it’s key to understand how immunotherapy works and what side effects to look for.

A beautiful tapestry reminded me to stay positive, even during a challenging time with cancer.

A Biologics License Application has been filed for the subcutaneous administration of Rybrevant for some patients with non-small cell lung cancer.

My health care team went back and forth on whether spots on my liver were cancerous, and that put me on an emotional rollercoaster.

With many groundbreaking cancer therapies on the horizon, it's also time to focus on up and coming cancer vaccines.

In the 2024 CURE Summer issue, we focused on a facet of cancer: the question of faith.

One expert explains why “the future of precision medicine” has arrived in lung cancer at the CURE® Educated Patient® Lung Cancer Summit.

LGBTQI+ patients with cancer are encouraged to seek positive relationships with care teams despite possible histories of minority stress.

The Food and Drug Administration approved Krazati plus Erbitux for pretreated KRAS G12C-mutant colorectal cancer.

Being a part of the cancer community means meeting new people, forming personal friendships and fostering those connections for others.

From Don Omar announcing being cancer free to “General Hospital” star John York talking about treatment for his two cancers, here’s what’s going on in the oncology space this week.

Tumor characteristics are used to determine the best method of combining therapies with surgery for non-small cell lung cancer, according to a presentation at the CURE® Educated Patient® Lung Cancer Summit.

Patients with chronic lymphocytic leukemia had better survival when treated with Calquence during earlier lines of therapy.

During the CURE® Educated Patient® Multiple Myeloma Summit, one expert explained the push to make CAR-T cell therapy available for patients sooner.

My reliable primary care physician was such an important asset in navigating multiple cancers.

Radiation plus targeted or immunotherapies could be beneficial for certain patients with lung cancer, and expert said at the CURE® Educated Patient® Lung Cancer Summit.

When I looked back on calendars and journals from my time with cancer, I was surprised to see that it was incredibly mundane.

The development of new or worsening anemia did not decrease Jakafi’s efficacy in treating primary or secondary myelofibrosis.

One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma.

Patients with lung cancer may have personalized treatment options after biomarker testing, an expert said at the CURE® Educated Patient® Lung Cancer Summit.

As a cancer survivor, I realize that life doesn’t always go the way we think it will, but it doesn’t erase the guilt.

Summer is time to pay particular attention to skin issues, including for patients with cancer undergoing treatments.

Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma tended to be more likely to stay on treatment and experience fewer heart toxicities with Calquence or Brukinsa.

Treatment for lung cancer has changed significantly with immunotherapy, an expert said during the CURE® Educated Patient® Lung Cancer Summit.